I have tasked three LLMs to produce some summaries of research and I attach those below. However, there is only one relatively straighforward conclusion I can come to at this point which is that Cystatin-C is a complex molecule and although there is an argument that low levels correlate with a longer healthier life that does not mean that lower levels are always the better thing to have.
Cystatin C (CST3): Positive and Negative Signalling Pathways
An overview of the evidence linking cystatin C to protease regulation, autophagy, inflammation, neuroprotection, immunity, fibrosis and tissue remodelling.
Introduction
Cystatin C, encoded by the CST3 gene, is widely recognised as an endogenous biomarker of kidney filtration. However, research indicates that cystatin C is more than a filtration marker. It is a biologically active protein involved in the regulation of protease activity, lysosomal function, inflammation, autophagy, extracellular matrix remodelling, neuroprotection and fibrosis.
Many of these effects arise because cystatin C inhibits lysosomal cysteine proteases, particularly cathepsins B, H, K, L and S. Through these interactions, cystatin C can influence signalling processes that are protective in some circumstances but detrimental in others.
Review: biological implications of cystatins and neuroprotection
1. The Central Signalling Mechanism
The principal molecular function of cystatin C is the inhibition of cysteine cathepsins. Cathepsins participate in several processes that have signalling consequences, including:
- Extracellular-matrix degradation
- Antigen processing and presentation
- Apoptosis and regulated cell death
- Inflammasome activation
- Cytokine and growth-factor processing
- Autophagic and lysosomal degradation
- Tissue repair and remodelling
Cystatin C therefore usually modifies signalling indirectly by changing the location, duration or intensity of cathepsin activity. It is not generally understood to operate like a conventional hormone binding to one specific cell-surface receptor.
Positive or Protective Signalling
2. Neuroprotection
Some of the strongest evidence for beneficial cystatin C activity comes from nervous-system models. Experimental studies associate cystatin C with:
- Reduced neuronal death following cellular stress or injury
- Protection against oxidative damage
- Resistance to excitotoxic and metabolic stress
- Improved clearance of damaged or aggregation-prone proteins
- Support for neuronal survival and repair
These effects may involve both cathepsin inhibition and signalling associated with autophagy and cellular stress responses.
3. Autophagy Activation
A frequently cited study by Tizon and colleagues reported that cystatin C induced autophagy and protected cells during nutritional and oxidative stress. The study linked extracellular cystatin C to reduced mTOR signalling and increased autophagic activity.
This finding helped broaden the interpretation of cystatin C from a passive protease inhibitor to a potential extracellular regulator of cellular recycling and survival pathways.
Tizon et al.: Induction of Autophagy by Cystatin C
4. Mitochondrial Protection and Mitophagy
The direct evidence that cystatin C specifically activates mitophagy is less developed than the evidence concerning general autophagy. Nevertheless, cystatin C may indirectly influence mitochondrial quality control by improving lysosomal function and supporting autophagic clearance.
Potential downstream consequences include:
- Improved removal of damaged mitochondria
- Reduced accumulation of mitochondrial reactive oxygen species
- Reduced lysosomal-to-mitochondrial death signalling
- Greater resistance to mitochondrial membrane permeabilisation
- Improved cellular survival during metabolic stress
5. Protection Against Protein Aggregation
Cystatin C has been investigated in relation to amyloid-β aggregation and Alzheimer-associated pathology. It can bind amyloid-β, and some experimental findings suggest that this interaction may reduce amyloid-β fibril formation or deposition.
Possible protective functions include:
- Binding soluble or aggregation-prone amyloid species
- Limiting fibril formation
- Supporting autophagic protein clearance
- Reducing protease-mediated neuronal damage
However, cystatin C itself can become amyloidogenic when destabilised by particular mutations or molecular conditions.
6. Anti-inflammatory Effects
Cathepsins released from damaged lysosomes can contribute to inflammasome activation, cytokine production and inflammatory cell death. By restraining extracellular or misplaced cathepsin activity, cystatin C may reduce inflammatory tissue injury.
Potential anti-inflammatory consequences include:
- Reduced cathepsin-mediated tissue damage
- Less lysosomal amplification of inflammasome signalling
- Reduced processing or release of certain inflammatory mediators
- Protection from protease-driven extracellular-matrix destruction
7. Maintenance of Extracellular-Matrix Integrity
Cathepsins can degrade structural proteins such as collagen, elastin and components of basement membranes. Cystatin C can therefore help limit excessive matrix degradation.
This may contribute to:
- Maintenance of vascular-wall integrity
- Protection against excessive elastin degradation
- Restraint of destructive inflammatory remodelling
- Reduced tumour invasion in some biological contexts
Negative or Potentially Harmful Signalling
8. Fibrosis and TGF-β Signalling
Cystatin C has a complex relationship with transforming growth factor beta, or TGF-β. TGF-β can increase CST3 expression and cystatin C secretion, particularly during tissue injury and remodelling.
Conversely, experimental research has also shown that cystatin C can antagonise aspects of TGF-β signalling. The net biological effect may therefore depend on:
- Cell type
- Stage of injury
- Local cathepsin activity
- Extracellular-matrix composition
- Concentration and duration of cystatin C exposure
In fibrotic disease, increased cystatin C may represent a protective attempt to limit proteolysis, a consequence of TGF-β activation, or a contributor to impaired matrix removal. These possibilities are not mutually exclusive.
Research on cystatin C antagonism of TGF-β signalling
9. Excessive Protease Inhibition
Cysteine cathepsins are not inherently harmful. They are required for normal physiology, including:
- Protein turnover
- Antigen processing
- Wound healing
- Bone remodelling
- Matrix renewal
- Cell migration
Excessive or poorly localised cystatin C activity could therefore interfere with necessary proteolysis. The possible result is impaired degradation, altered immunity or reduced tissue remodelling.
10. Tumour Biology
Cancer demonstrates the context-dependent nature of cystatin C signalling. By inhibiting cathepsins, cystatin C may reduce tumour-cell invasion through extracellular matrices. This could suppress local invasion and metastasis.
In other contexts, however, cystatin C may support tumour survival, modify immune surveillance or inhibit proteases required for an effective antitumour response. Its effects vary between tumour types, stages and tissue environments.
Potential antitumour effects include:
- Reduced extracellular-matrix degradation
- Reduced invasion and migration
- Inhibition of metastasis-associated cathepsins
Potential tumour-supporting effects include:
- Protection of tumour cells from protease-mediated death
- Alteration of antigen presentation
- Suppression of immune-cell protease functions
- Changes in autophagy that favour tumour-cell survival
11. Immune Regulation and Antigen Presentation
Cathepsin S is important for processing the invariant chain associated with MHC class II molecules. It therefore contributes to antigen presentation to CD4-positive T cells.
Because cystatin C can inhibit cathepsin S, it may alter:
- MHC class II antigen processing
- Dendritic-cell function
- CD4 T-cell activation
- Autoimmune responses
- Immune responses to infection or tumours
This inhibition might be beneficial where antigen presentation drives autoimmunity, but detrimental where an effective adaptive immune response is required.
12. Impaired Lysosomal Proteolysis
Moderate restriction of cathepsin activity may protect cells from lysosomal leakage and uncontrolled proteolysis. Excessive inhibition, however, could reduce lysosomal degradation capacity.
Potential consequences include:
- Incomplete protein degradation
- Accumulation of damaged cellular material
- Reduced autophagic completion
- Disturbed organelle recycling
- Altered nutrient sensing
The effect of cystatin C on autophagy may therefore be biphasic: signalling can initiate or support autophagy under some conditions, while excessive protease inhibition could compromise the degradative phase under others.
Major Signalling Systems Associated with Cystatin C
- Cysteine-cathepsin regulation
- Lysosomal stress signalling
- Autophagy
- mTOR-associated nutrient signalling
- TGF-β signalling
- Inflammasome signalling
- NF-κB-associated inflammation
- Antigen presentation
- Amyloid aggregation
- Extracellular-matrix remodelling
- Apoptotic and lysosomal cell-death pathways
- Mitochondrial quality control
Relevance to Ageing
Cystatin C is relevant to ageing because ageing involves changes in lysosomal function, autophagy, inflammation, extracellular-matrix turnover, immunity and mitochondrial quality control.
Potentially beneficial effects
- Promotion of protective autophagy
- Reduction of uncontrolled cathepsin activity
- Protection against inflammatory tissue destruction
- Reduction of protein aggregation
- Neuroprotection
- Support for extracellular-matrix integrity
Potentially detrimental effects
- Impaired lysosomal degradation when inhibition is excessive
- Reduced immune antigen processing
- Reduced adaptive tissue remodelling
- Possible participation in fibrotic matrix accumulation
- Context-dependent support for tumour-cell survival
- Amyloid formation by structurally unstable cystatin C
Elevated circulating cystatin C in older people cannot automatically be interpreted as increased beneficial signalling. It may reflect reduced kidney filtration, increased production during inflammation or tissue stress, glucocorticoid exposure, thyroid effects, altered body composition or a combination of these factors.
Possible Relationship to the Mitochondrial Citrate–Acetyl-CoA Axis
Cystatin C could plausibly influence mitochondrial and nuclear metabolism through the lysosome–autophagy pathway:
- Cystatin C modifies lysosomal cathepsin activity.
- This may alter autophagy and mitochondrial quality control.
- Improved mitochondrial quality may help preserve respiratory function and membrane potential.
- Preserved mitochondrial function may support citrate synthesis and export.
- Cytosolic citrate can be converted by ATP-citrate lyase into acetyl-CoA.
- Acetyl-CoA availability can influence histone acetylation, transcription and RNA processing.
Overall Interpretation
Cystatin C is best understood as a regulator of the balance between necessary proteolysis and damaging protease activity. Its effects are strongly dependent on concentration, cellular location, tissue type, disease stage and the activity of the cathepsins that it inhibits.
Its positive effects include neuroprotection, restraint of destructive inflammation, support for autophagy and protection of extracellular structures. Its negative effects may include impaired antigen presentation, inadequate lysosomal degradation, reduced tissue remodelling, context-dependent tumour support and possible participation in fibrotic matrix accumulation.
Cystatin C should therefore not be classified simply as either protective or harmful. It acts as a context-dependent modulator of the lysosome–cathepsin–autophagy–inflammation network.
Selected References and Further Reading
-
Review of cystatins and neuroprotection.
A broad discussion of cystatin-family biology, cathepsin inhibition,
autophagy and nervous-system effects.
https://pmc.ncbi.nlm.nih.gov/articles/PMC10895963/ -
Tizon B et al. Induction of Autophagy by Cystatin C.
PLoS ONE. 2010;5(3):e9819. This experimental paper reported
cystatin C-associated autophagy induction, mTOR inhibition and
protection during cellular stress.
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0009819 -
Sokol JP and Schiemann WP. Cystatin C antagonizes transforming
growth factor beta signalling.
Research examining the relationship between cystatin C and TGF-β
pathway activity.
https://pubmed.ncbi.nlm.nih.gov/15037657/ -
Reviews of cystatin C in disease and immunity.
These discuss the relationship between cystatin C, cathepsin
regulation, immune function, inflammation and disease-associated
signalling.
https://onlinelibrary.wiley.com/doi/full/10.1038/icb.2014.121 -
Review of cathepsins in cancer.
Provides background on the proteases through which many of cystatin
C's cancer-related effects are mediated.
https://www.jcancer.org/v14p2344.htm
Positive and Negative Signalling by Cystatin C
Cystatin C (encoded by the CST3 gene) is primarily recognized in clinical medicine as a stable biomarker for glomerular filtration rate, but exhaustive molecular research demonstrates that it functions actively as an extracellular and intracellular signaling mediator. Beyond its canonical role as a reversible inhibitor of family C1 cysteine cathepsins (such as cathepsins B, H, K, L, and S), Cystatin C modulates multiple signaling cascades that drive protective (“positive”) or pathological (“negative”) outcomes depending on tissue context, concentration, and disease state.
Positive (Protective and Homeostatic) Signalling
1. Antagonism of TGF-β and Prevention of Epithelial-Mesenchymal Transition (EMT)
- Cystatin C acts as an antagonist to transforming growth factor-beta (TGF-β) receptor signaling by physically binding to the TGF-β type II receptor (TβR-II) (Sokol et al., 2005; Zhang & Zhan, 2023).
- By preventing TGF-β ligand engagement, Cystatin C suppresses downstream Smad2/3 phosphorylation and non-Smad cascades, thereby preventing EMT, loss of apical-basal cell polarity, and metastatic cell migration in normal epithelial cells and early-stage carcinoma models (Sokol et al., 2005).
2. Induction of Protective Autophagy via mTOR Suppression
- In neuronal systems subjected to oxidative or nutrient stress, Cystatin C promotes cell survival through the activation of complete, functional autophagy (Tizon et al., 2010).
- This mechanism occurs independently of cathepsin B inhibition, operating instead via downstream suppression of the mechanistic target of rapamycin (mTOR) pathway, facilitating lysosomal clearance of neurotoxic protein aggregates (Tizon et al., 2010).
3. Modulation of Immune Homeostasis and Pathogen Defense
- Cystatin C suppresses aberrant extracellular matrix (ECM) degradation by inflammatory cathepsins and orchestrates cytokine shifts from Th2- to Th1-mediated immune responses (Zi & Xu, 2018).
- It directly interferes with microbial and viral replication through selective protease inhibition and modulation of nitric oxide (NO) generation (Zi & Xu, 2018).
Negative (Pathological and Maladaptive) Signalling
1. MAPK/ERK Activation and Modulated Tumor Invasiveness
- Alterations in Cystatin C expression dynamically shift mitogen-activated protein kinase (MAPK) signaling. In certain malignancies such as prostate cancer, loss or dysregulation of Cystatin C cross-talks with the androgen receptor (AR) and ERK2 cascades (Wegiel et al., 2009).
- Perturbations in the balance between Cystatin C and endogenous cysteine cathepsins allow unchecked proteolytic remodeling of the basement membrane, stimulating tumor motility and survival pathways (Wegiel et al., 2009; Zhang & Zhan, 2023).
2. Context-Dependent Modulation of Apoptosis and Chronic Inflammation
- In rheumatoid synovium and chronic inflammatory tissue, elevated Cystatin C can become insufficient to arrest chronic cathepsin-mediated tissue damage or may interfere with necessary clearance of apoptotic debris (Zi & Xu, 2018).
- Depending on the cellular microenvironment, Cystatin C can exert contradictory effects on apoptosis—protecting cells under oxidative stress while altering immune cell lifespan in autoimmune settings (Zi & Xu, 2018).
Summary of Signalling Pathways
| Pathway / Target | Mechanism of Action | Biological Context / Outcome | Reference |
|---|---|---|---|
| TGF-β / TβR-II | Direct competitive receptor binding; blocks TGF-β interaction | Positive: Suppresses EMT, tumor invasion, and metastasis | Sokol et al. (2005); Zhang & Zhan (2023) |
| mTOR / Autophagy | mTOR inhibition; upregulation of autophagic flux | Positive: Neuroprotection against oxidative & nutrient stress | Tizon et al. (2010) |
| MAPK / ERK2 & AR | Downregulation shifts ERK phosphorylation and AR signaling | Negative: Promotes aggressive tumor phenotypes when lost | Wegiel et al. (2009) |
| Immune / Cytokine Networks | Modulates NO generation and Th1/Th2 balance | Dual: Anti-microbial defense vs. chronic autoimmune retention | Zi & Xu (2018) |
References
Sokol, J. P., Neil, J. R., Schiemann, B. J., & Schiemann, W. P. (2005). The use of cystatin C to inhibit epithelial–mesenchymal transition and morphological transformation stimulated by transforming growth factor-β. Breast Cancer Research, 7, Article 1312. https://doi.org/10.1186/bcr1312
Cited by: 123
Tizon, B., Sahoo, S., Yu, H., Gauthier, S., Kumar, A. R., Mohan, P., Figliola, M., Pawlik, M., Grubb, A., Uchiyama, Y., Bandyopadhyay, U., Cuervo, A. M., Nixon, R. A., & Levy, E. (2010). Induction of autophagy by cystatin C: A mechanism that protects murine primary cortical neurons and neuronal cell lines. PLoS ONE, 5(3), Article e9819. https://doi.org/10.1371/journal.pone.0009819
Cited by: 183
Wegiel, B., Jiborn, T., Abrahamson, M., Helczynski, L., Otterbein, L., Persson, J. L., & Bjartell, A. (2009). Cystatin C is downregulated in prostate cancer and modulates invasion of prostate cancer cells via MAPK/Erk and androgen receptor pathways. PLoS ONE, 4(11), Article e7953. https://doi.org/10.1371/journal.pone.0007953
Cited by: 99
Zhang, Z., & Zhan, F. (2023). Type 2 cystatins and their roles in the regulation of human immune response and cancer progression. Cancers, 15(22), Article 5363. https://doi.org/10.3390/cancers15225363
Cited by: 26
Zi, M., & Xu, Y. (2018). Involvement of cystatin C in immunity and apoptosis. Immunology Letters, 196, 80–90. https://doi.org/10.1016/j.imlet.2018.01.006
Cited by: 204
Literature survey · compiled from PubMed · August 2026
Cystatin C as a signalling molecule Eighteen papers on the protective and pathogenic arms of CST3, and the contradiction between them that the literature has not resolved.
Why this is worth separating out
Cystatin C is used clinically as a glomerular filtration marker, and that use has almost entirely eclipsed its biology. It is in fact a secreted 13 kDa protein expressed by all nucleated cells, and it does at least three distinct things: inhibits cysteine cathepsins, signals independently of protease inhibition, and participates in the senescence-associated secretory phenotype.
Running through this literature is the Δ14CystC mutant — a cystatin C variant engineered to lose cathepsin-inhibitory capacity while retaining the rest of the molecule. Where an effect survives in Δ14CystC, it is genuine signalling. Where it does not, it is protease inhibition wearing a signalling costume. Several of the strongest papers below turn on exactly this distinction.
Protective signalling
mTOR inhibition and autophagy induction
The cleanest demonstration of cathepsin-independent signalling. Cystatin C protected cultured cortical neurons against nutrient deprivation, oxidative stress, colchicine and staurosporine. Cathepsin B inhibition was not required. Protection ran through mTOR-mediated autophagy and was abolished by beclin 1 knockdown — establishing autophagy as the necessary mechanism rather than an incidental correlate.
10.1371/journal.pone.0009819VEGF induction and angiogenesis
In MPTP and rotenone Parkinson's models, cystatin C injected into the substantia nigra raised secreted VEGF, increased autophagy markers and reduced α-synuclein accumulation, signalling via PKC-α and ERK1/2 acting on Nurr1. The two arms are coupled — blocking autophagy suppressed VEGF output, so this is one nested cascade rather than two independent pathways.
10.1038/cddis.2017.240Blood-brain barrier integrity
Improved barrier integrity after ischaemic injury in mice, acting via caveolin-1 upregulation with downstream effects on occludin and tight junction assembly.
10.1111/jnc.14894Direct neuroprotection in vivo
Prevented degeneration of nigral dopaminergic neurons in rats, replicated both in vitro and in vivo.
10.1016/j.nbd.2004.08.012Amyloid-β interaction
Localised the amyloid-β binding activity to the C-terminal fragment spanning residues 101–117, which inhibits fibril formation. This gives a defined, druggable peptide target rather than a whole-protein effect.
10.1002/jmr.2581Protective mechanisms by cystatin C in neurodegenerative diseases
The best single entry point. Argues that elevation of cystatin C in stroke, Alzheimer's and Parkinson's is an endogenous protective response rather than a marker of injury, integrating cathepsin B inhibition, autophagy induction, cell proliferation and amyloid anti-aggregation.
10.2741/s170Cystatin C in Alzheimer's disease
Covers the CST3 polymorphism associated with Alzheimer's risk, and the co-localisation of cystatin C with amyloid-β in both plaque cores and vessel walls.
10.3389/fnmol.2012.00079TGF-β receptor antagonism — the best-characterised true signalling function
This deserves its own section because the mechanism is unusually well nailed down, and because it is genuinely double-edged.
Cystatin C antagonises TGF-β signalling in normal and cancer cells
Cystatin C binds the TGF-β type II receptor and antagonises TGF-β binding to it. The Δ14CystC mutant — impaired in cathepsin inhibition — still blocked TGF-β-dependent gene expression and TGF-β-dependent invasion, proving the effect is receptor-level, not proteolytic. The authors also showed TGF-β upregulates cystatin C transcript and protein, closing a negative feedback loop: TGF-β induces its own antagonist.
PMID 15037657 — no DOI indexed in PubMed for this record.
Inhibition of epithelial-mesenchymal transition
Both wild-type cystatin C and Δ14CystC blocked TGF-β-stimulated EMT in mammary epithelial cells, preventing actin cytoskeletal rearrangement and E-cadherin downregulation, and abolished anchorage-independent growth in fibroblasts.
10.1186/bcr1312TGF-β is tumour-suppressive in early epithelial lesions and tumour-promoting later. An endogenous TGF-β antagonist is therefore protective or harmful depending entirely on disease stage. The same logic applies in fibrosis and in vascular remodelling, where TGF-β drives the very cystatin C induction that then restrains it.
The vascular literature
Cystatin C deficiency in human atherosclerosis and aortic aneurysms
The founding observation. Cystatin C is normally expressed in vascular smooth muscle but severely depleted in atherosclerotic and aneurysmal aortic lesions, while cathepsins S and K are overexpressed. Across 122 ultrasound-screened patients, aortic diameter correlated inversely with serum cystatin C. TGF-β1 treatment induced cystatin C secretion and blocked smooth muscle elastolytic activity.
10.1172/JCI7709Cystatin C deficiency promotes inflammation in angiotensin II-induced AAA
The causal experiment, and the strongest single piece of evidence here. CystC⁻/⁻ApoE⁻/⁻ mice given angiotensin II developed larger lumenal diameters, worse elastin fragmentation, fewer medial smooth muscle cells, a 5.5-fold rise in cathepsin activity, a doubling of macrophage content and a ninefold increase in CD4⁺ T cells. Cystatin C absence drives the lesion; it is not merely correlated with it.
10.2353/ajpath.2010.090381Cystatin C gene variation and aneurysm expansion
424 patients with small aneurysms (4.0–5.5 cm) followed by ultrasound. The rare AA genotype at the +148 signal peptide polymorphism showed slower growth after adjustment (p = 0.027). The authors themselves describe the association as weak, and smoking history was a stronger predictor (p = 0.003).
10.1002/bjs.4364Cellular localisation of cathepsins in the aneurysm wall
Histological confirmation across 32 aneurysm walls versus 10 donor aortas: weak cystatin C expression throughout the lesion alongside markedly elevated cathepsins B, D, K, L and S, most intense in macrophages.
10.1111/j.1365-2613.2012.00819.xElastin is essentially non-renewable in adult humans, laid down largely in childhood. There is no meaningful rebuild pathway, so inhibition of degradation is the only available defence. This is what makes the cathepsin/cystatin C balance mechanistically decisive in arterial ageing rather than merely descriptive.
Pathogenic signalling
Cystatin C is a SASP protein
Measured 77 SASP Atlas proteins by aptamer proteomics in 1,201 participants across the BLSA/GESTALT and InCHIANTI cohorts. Twenty-eight tracked with age; cystatin C was one of only seven associated with three or more ageing traits, alongside GDF-15 and IGFBP-2, linking to both inflammatory markers and physical function.
10.1093/gerona/glad265CST3 as a coronary artery disease susceptibility gene
The most direct challenge to the protective narrative. Integrating RNA-array data from senescent human coronary arterial endothelial cells and aortic smooth muscle cells with CAD GWAS data, CST3 emerged as a prioritised susceptibility gene — elevated in senescent vascular cells, aged arteries and early atherosclerosis. In vitro, cystatin C enhanced monocyte-endothelial adhesion. Ligand-receptor pairing implicated COL4A1–ITGA1 and LPL–LRP1; knockdown of COL4A1 or ITGA1 reduced adhesion.
10.1093/gerona/glae070Paradoxical cathepsin feedback
Directly relevant to any intervention aimed at raising cystatin C. In MDA-MB-231 cells, cystatin C treatment produced opposing responses in two cathepsins: active cathepsin S rose while active cathepsin L fell. Cells selectively sustained active cathepsin S despite subnanomolar inhibitory constants, via differences in trafficking, compartmentalisation, co-localisation with endocytosed inhibitor, and protein turnover time. The authors' conclusion is the important one: cellular compensation means effects cannot be predicted from inhibitor kinetics alone.
10.1016/j.biocel.2016.08.030Cathepsin/cystatin C balance as a predictive metric
Monocyte cathepsin and cystatin C profiles, plus kinase activation signals, trained a multivariate model predicting macrophage-assisted breast cancer cell invasion. Applied prospectively to monocytes from nine mastectomy patients, the highest predicted invasion indices matched the more invasive initial diagnoses. Small n, but proof of principle that the ratio carries information the absolute level does not.
10.1038/srep13855Epigenetic regulation of cystatins in cancer
Review of DNA methylation-dependent silencing of cystatin genes in breast, pancreatic, brain and lung cancer. Cystatin C transcript was found downregulated in roughly half of human malignancies surveyed by Sokol and Schiemann, particularly stomach, uterus, colon and kidney — consistent with a tumour-suppressive role whose loss is selected for.
10.2741/3254The unresolved contradiction
Two findings, both in vessel wall cells, both reasonably conducted, point in opposite directions.
Cystatin C protects the vessel wall
Shi 1999 · Schulte 2010
Cystatin C damages the vessel wall
Zhu 2024
Candidate reconciliations, in rough order of plausibility
The literature does not currently resolve this, and anyone claiming otherwise should be treated with suspicion.
Implications for intervention
Three problems stand between this biology and anything actionable.
The measurement problem
Serum cystatin C rises both from reduced glomerular clearance and from increased production — SASP, glucocorticoids, thyroid hormone, TGF-β signalling. A blood level cannot distinguish healthy local induction from declining renal function. Interpreting a rise requires an independent filtration measure.
The direction problem
Given section 06, it is not established whether raising cystatin C is desirable, and the most recent vascular data argue it is not.
The lever problem
The known routes to raising expression are unattractive. TGF-β induction brings fibrosis and, per Sokol, is partly self-cancelling. Glucocorticoids carry obvious costs. Thyroid hormone is not a free parameter. And Wilder 2016 indicates exogenous cystatin C provokes compensatory cathepsin S elevation.
Where the tractable target probably sits
The Wang 2016 C-terminal 101–117 fragment, and the Δ14CystC construct more generally, suggest the useful approach is dissociating the arms — deploying the signalling function without the protease inhibition, or vice versa — rather than moving the whole molecule up or down. That is a protein engineering problem, not a supplementation one.
Gaps worth noting
Compiled from PubMed searches, August 2026. All primary claims traceable to the DOI links above; where a stated interpretation goes beyond a paper's own conclusions it is flagged in the text. Pole markers indicate the direction of each paper's finding, not its methodological quality — the two 2024 senescence papers are among the strongest here and sit on the pathogenic side.
Comments